Table 1 Baseline patient demographics and disease characteristics
ITT population | Biomarker population | |||
|---|---|---|---|---|
Adalimumab 40 mg q2w (n = 185) | Sarilumab 200 mg q2w (n = 184) | Adalimumab 40 mg q2w (n = 154) | Sarilumab 200 mg q2w (n = 153) | |
Age, years | 53.6 (11.9) | 50.9 (12.6) | 53.3 (12.0) | 50.4 (12.5) |
Sex, female, % | 81.1 | 85.3 | 78.6 | 83.7 |
Duration of RA, years | 6.6 (7.8) | 8.1 (8.1) | 6.6 (8.1) | 7.9 (8.1) |
ACPA positive, % | 76.7 | 75.3 | 76.2 | 73.8 |
RF positive, % | 64.8 | 66.9 | 63.8 | 66.0 |
Treated with 1/2/≥ 3 prior csDMARDs/immunosuppressive agents, % | 47.6/31.4/21.1 | 45.1/31.0/23.9 | 48.1/31.8/20.1 | 46.4/32.0/21.6 |
Oral corticosteroid use, % | 56.2 | 53.3 | 57.1 | 51.6 |
Tender joint count | 26.7 (13.6) | 28.0 (13.2) | 26.9 (13.9) | 28.1 (13.4) |
Swollen joint count | 17.5 (10.3) | 18.6 (10.7) | 17.3 (10.1) | 18.5 (10.6) |
HAQ-DI | 1.6 (0.6) | 1.6 (0.6) | 1.6 (0.6) | 1.6 (0.6) |
CRP, mg/L | 24.1 (31.0) | 17.4 (21.3) | 23.6 (31.1) | 17.4 (21.9) |
DAS28-ESR | 6.8 (0.8) | 6.8 (0.8) | 6.8 (0.8) | 6.8 (0.8) |
DAS28-CRP | 6.0 (0.9) | 6.0 (0.9) | 6.0 (0.9) | 6.0 (0.9) |
CDAI | 42.4 (12.0) | 43.6 (12.1) | 42.8 (11.9) | 43.8 (12.0) |
Pain VAS (0–100 mm) | 71.4 (19.0) | 71.6 (18.7) | 71.3 (18.6) | 71.2 (19.1) |
Patient global VAS (0–100 mm) | 67.8 (18.4) | 68.0 (17.5) | 68.6 (18.2) | 67.8 (17.9) |
SF-36 PCS | 31.4 (6.6) | 30.7 (6.2) | 31.5 (6.5) | 30.4 (6.2) |
SF-36 MCS | 37.1 (11.8) | 36.7 (10.7) | 37.4 (12.4) | 37.0 (11.2) |
Morning stiffness VAS (0–100 mm) | 68.0 (21.4) | 70.8 (19.0) | 68.2 (21.7) | 70.6 (18.8) |
FACIT-fatigue (0–52) | 24.0 (10.3) | 24.0 (9.0) | 23.9 (10.4) | 23.4 (9.1) |
Physician global VAS (0–100 mm) | 66.0 (17.1) | 66.3 (15.7) | 66.2 (16.4) | 67.3 (14.9) |
RAID (0–10) | 6.4 (2.0) | 6.7 (1.7) | 6.4 (2.1) | 6.6 (1.7) |